Bioharvest Sciences
Bioharvest Sciences' revenue rose 37.0% to $34 million in fiscal 2025. Its operating margin was −16.2%, up from −27.8% a year earlier. Free cash flow was −$10 million.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on equity is net income as a share of shareholders' equity.
What Bioharvest Sciences does
BioHarvest Sciences is a biotechnology company based in Israel that grows plant cells in large tanks called bioreactors, so it can produce the useful ingredients of fruits and plants without growing the plants themselves. It says its method uses no genetic modification. Its main product is VINIA, a red grape cell powder rich in resveratrol and other polyphenols, sold as capsules and chews and in coffee, tea and drink powders, mainly to consumers in the United States and Israel.
It has two business units. The Products unit develops, makes and sells VINIA dietary supplements and functional foods and drinks. The company says it earns about 80 percent of its revenue directly from shoppers through its own websites and most of the rest on Amazon. The CDMO Services unit (contract development and manufacturing) develops plant-based active molecules for pharmaceutical, cosmetics, supplement and nutrition companies under service agreements. It names large biotechnology, supplement, cosmetics and contract manufacturing companies, and research institutions, among its competitors.
Its total revenue was US$34,508,000 in 2025. It had 89 employees at the end of 2025, and its facilities are in Rehovot and Yavne, Israel, where it is building a new manufacturing plant. Its shares moved to the Nasdaq in November 2024.
Its biggest risks, as it describes them
- Negative operating cash flow, and doubt about its ability to continue as a going concern.
- War and unrest involving Israel, where its management, staff and only manufacturing plant are located.
- Its reliance on online sales, including on Amazon, where a dispute could cut off a share of its sales.
- Product recalls or regulatory action if its supplements are found not to meet the rules or cause side effects.
- Intense competition from larger companies in supplements, cosmetics and contract manufacturing.
Income statement
Bioharvest Sciences lost money in fiscal 2025: a net loss of $11 million.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY23 | FY24 | FY25 |
|---|---|---|---|
| Cash and short-term investments | 5 | 2 | 23 |
| Debt incl. finance leases | — | — | — |
| Net debt (negative means net cash) | — | — | — |
| Net debt to EBITDA | — | — | — |
| Debt to equity | — | — | — |
| Interest coverage | −18.7x | — | — |
| Current ratio | 0.3x | 0.6x | 4.0x |
| Quick ratio | 0.2x | 0.3x | 3.4x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY24 | FY25 |
|---|---|---|
| Piotroski F-score | — | — |
| Rule of 40 | 61.0% | 9.2% |
| Altman Z'' | −16.07 | −3.80 |
| Accruals ratio | −31.1% | −10.8% |
The nine F-score tests
| Test | FY24 | FY25 |
|---|---|---|
| Net income is positive | Fail | Fail |
| Cash from operations is positive | Fail | Fail |
| Return on assets rose | — | Pass |
| Cash from operations exceeds net income | Pass | Pass |
| Debt fell relative to assets | — | — |
| Current ratio rose | Pass | Pass |
| Share count didn't rise | — | — |
| Gross margin rose | Pass | Pass |
| Revenue rose relative to assets | — | Fail |
| F-score | — | — |
Compare
Put Bioharvest Sciences side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Bioharvest Sciences | FY25 | 37.0% | −16.2% | −27.8% | — | — | — | |
| Axil Brands | FY26 | 17.5% | 9.7% | −0.3% | — | — | — | Compare |
| Natural Health Trends | FY25 | −7.4% | −4.5% | −15.2% | — | — | — | Compare |
| Solesence | FY25 | 18.6% | 4.2% | — | — | — | — | Compare |
| Bon Natural Life | FY25 | −21.7% | −8.7% | 0.7% | −2.2% | — | 2 | Compare |
3 years of figures
| Fiscal year | FY23 | FY24 | FY25 |
|---|---|---|---|
| Income statement | |||
| Revenue | 13 | 25 | 34 |
| Revenue growth | — | 98.8% | 37.0% |
| Gross profit | 6 | 14 | 20 |
| Research and development | 3 | 5 | 5 |
| Operating income | −10 | −7 | −6 |
| Net income | −13 | −13 | −11 |
| Diluted EPS (US$) | — | — | — |
| Diluted shares (millions) | — | — | — |
| Cash flow | |||
| Cash from operations | −8 | −7 | −7 |
| Capital expenditure | 2 | 3 | 2 |
| Free cash flow | −10 | −10 | −10 |
| Dividends paid | 0 | 0 | 0 |
| Share buybacks | 0 | 0 | 0 |
| Acquisitions | 0 | 0 | 0 |
| Stock-based compensation | 1 | 1 | — |
| Balance sheet at fiscal year end | |||
| Cash and short-term investments | 5 | 2 | 23 |
| Debt incl. finance leases | — | — | — |
| Total assets | 15 | 25 | 48 |
| Total liabilities | 30 | 24 | 22 |
| Shareholders' equity | −15 | 1 | 25 |
| Margins and ratios | |||
| Gross margin | 44.5% | 55.4% | 59.3% |
| Operating margin | −78.7% | −27.8% | −16.2% |
| Net margin | −99.2% | −51.3% | −32.3% |
| Free cash flow margin | −78.9% | −37.8% | −27.8% |
| Rule of 40 (growth + FCF margin) | — | 61.0% | 9.2% |
| Return on capital | — | — | — |
| Return on equity | — | — | −83.2% |
| Return on assets | — | −64.6% | −30.6% |
| Net debt to EBITDA | — | — | — |